Navigation Links
Avantra Biosciences Announces the Launch of a Rapid Assay Prototyping Service
Date:6/6/2011

WOBURN, Mass., June 6, 2011 /PRNewswire/ -- Avantra® Biosciences, a leading innovator in protein diagnostics, announces a Rapid Assay Prototyping Service. Avantra's new service allows researchers to cost effectively accelerate their research efforts using custom designed biomarker assays developed on Avantra's proven QPDx™ BioChip platform. The QPDx™ platform offers users rapid, easy-to-use, quantitative multiplex protein assays using catalog or custom reagents.

Avantra's service offering provides researchers and clinicians with rapidly prototyped disease specific biomarker assays. To provide this service, Avantra leverages pre-validated antibody pairs that can be further optimized for specific research needs. In addition, Avantra can design QPDx™ assays that use a client's own immunoassay reagents.  Avantra's assays can be used for screening drug targets, pathway analysis, and disease state biomarker profiling.  

The Avantra Biomarker System is currently being evaluated and used by a variety of health care institutions and research organizations for both research and potential point-of-care applications. This service greatly increases the versatility of the Avantra system providing researchers and clinician's maximum operational efficiencies and reduced costs.

About Avantra Biosciences Corporation

Avantra Biosciences, a Courtagen Life Sciences Company, is a privately held diagnostics company that has pioneered next-generation technology for protein biomarker analysis.  Avantra's integrated system consists of the Q400 Biomarker Workstation and the QPDx™ BioChip, which enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) at their lab bench or clinical trial site.

www.AvantraBio.com


'/>"/>
SOURCE Avantra Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Avantra Biosciences Offers Its Proprietary PATH® Slides for Sale
2. GeneLink Biosciences Expands its Scientific Advisory Board to Support New Product Lines
3. Ardea Biosciences to Present at Upcoming Investor Conferences
4. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
5. Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum
6. TEI Biosciences Wins SBANE 2011 New England Innovation Award
7. Transposagens piggyBac™ Vectors to be Distributed by System Biosciences
8. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
9. Cell Biosciences Announces Issuance of Three US Patents
10. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
11. TEI Biosciences Chairman, President and CEO Yiannis Monovoukas Named Ernst & Young Entrepreneur Of The Year® 2011 New England Award Semifinalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):